Skip to main content

All three major indices traded up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 57 points (0.3%) at 17,459 as of Thursday, Aug. 13, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,426 issues advancing vs. 1,512 declining with 179 unchanged.

The Electronics industry as a whole closed the day down 0.6% versus the S&P 500, which was up 0.2%. Top gainers within the Electronics industry included

Digital Power

(

DPW

), up 4.3%,

Vicon Industries

(

VII

), up 8.2%,

Wafergen Bio-systems

(

TheStreet Recommends

WGBS

), up 2.3%,

Sequans Communications

(

SQNS

), up 1.6% and

Actions Semiconductor

(

ACTS

), up 2.1%.

TheStreet Ratings Group would like to highlight 3 stocks pushing the industry higher today:

Actions Semiconductor

(

ACTS

) is one of the companies that pushed the Electronics industry higher today. Actions Semiconductor was up $0.03 (2.1%) to $1.45 on average volume. Throughout the day, 47,956 shares of Actions Semiconductor exchanged hands as compared to its average daily volume of 59,100 shares. The stock ranged in a price between $1.40-$1.45 after having opened the day at $1.43 as compared to the previous trading day's close of $1.42.

Actions Semiconductor Co., Ltd., a fabless semiconductor company, designs, develops, and markets system-on-a-chip (SoC) products and solutions worldwide. Actions Semiconductor has a market cap of $118.7 million and is part of the technology sector. Shares are down 26.8% year-to-date as of the close of trading on Wednesday. Currently there are no analysts who rate Actions Semiconductor a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Actions Semiconductor as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, disappointing return on equity and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on ACTS go as follows:

  • ACTIONS SEMICNDCTR LTD -ADR's earnings per share declined by 12.5% in the most recent quarter compared to the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. During the past fiscal year, ACTIONS SEMICNDCTR LTD -ADR swung to a loss, reporting -$0.48 versus $0.01 in the prior year.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Semiconductors & Semiconductor Equipment industry and the overall market, ACTIONS SEMICNDCTR LTD -ADR's return on equity significantly trails that of both the industry average and the S&P 500.
  • Looking at the price performance of ACTS's shares over the past 12 months, there is not much good news to report: the stock is down 30.44%, and it has underformed the S&P 500 Index. In addition, the company's earnings per share are lower today than the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • Regardless of the drop in revenue, the company managed to outperform against the industry average of 10.6%. Since the same quarter one year prior, revenues slightly dropped by 7.4%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
  • 39.82% is the gross profit margin for ACTIONS SEMICNDCTR LTD -ADR which we consider to be strong. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -47.69% is in-line with the industry average.

You can view the full analysis from the report here:

Actions Semiconductor Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

At the close,

Sequans Communications

(

SQNS

) was up $0.02 (1.6%) to $1.28 on light volume. Throughout the day, 14,028 shares of Sequans Communications exchanged hands as compared to its average daily volume of 50,400 shares. The stock ranged in a price between $1.25-$1.29 after having opened the day at $1.28 as compared to the previous trading day's close of $1.26.

Sequans Communications S.A., together with its subsidiaries, engages in fabless designing, developing, and supplying 4G LTE and WiMAX semiconductor solutions for wireless broadband applications. Sequans Communications has a market cap of $68.0 million and is part of the technology sector. Shares are up 5.9% year-to-date as of the close of trading on Wednesday. Currently there are 5 analysts who rate Sequans Communications a buy, no analysts rate it a sell, and none rate it a hold.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreet Ratings rates Sequans Communications as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on SQNS go as follows:

  • The debt-to-equity ratio of 1.14 is relatively high when compared with the industry average, suggesting a need for better debt level management. Along with the unfavorable debt-to-equity ratio, SQNS maintains a poor quick ratio of 0.86, which illustrates the inability to avoid short-term cash problems.
  • Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Semiconductors & Semiconductor Equipment industry and the overall market, SEQUANS COMMUNICATIONS -ADR's return on equity significantly trails that of both the industry average and the S&P 500.
  • Net operating cash flow has significantly decreased to -$8.20 million or 143.06% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
  • SQNS has underperformed the S&P 500 Index, declining 19.05% from its price level of one year ago. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
  • The gross profit margin for SEQUANS COMMUNICATIONS -ADR is rather high; currently it is at 53.68%. Despite the high profit margin, it has decreased significantly from the same period last year. Despite the mixed results of the gross profit margin, SQNS's net profit margin of -94.29% significantly underperformed when compared to the industry average.

You can view the full analysis from the report here:

Sequans Communications Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Wafergen Bio-systems

(

WGBS

) was another company that pushed the Electronics industry higher today. Wafergen Bio-systems was up $0.03 (2.3%) to $1.36 on heavy volume. Throughout the day, 268,069 shares of Wafergen Bio-systems exchanged hands as compared to its average daily volume of 43,600 shares. The stock ranged in a price between $1.30-$1.63 after having opened the day at $1.34 as compared to the previous trading day's close of $1.33.

WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for gene expression quantification, genotyping, and stem cell research for the life sciences and pharmaceutical drug discovery industries in the United States, Canada, Europe, and the Asia Pacific. Wafergen Bio-systems has a market cap of $7.4 million and is part of the technology sector. Shares are down 55.7% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Wafergen Bio-systems a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Wafergen Bio-systems as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself.

Highlights from TheStreet Ratings analysis on WGBS go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry. The net income has significantly decreased by 81.7% when compared to the same quarter one year ago, falling from -$2.10 million to -$3.82 million.
  • WGBS's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 87.36%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, WAFERGEN BIO-SYSTEMS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • WGBS, with its decline in revenue, slightly underperformed the industry average of 5.5%. Since the same quarter one year prior, revenues slightly dropped by 7.1%. The declining revenue has not hurt the company's bottom line, with increasing earnings per share.
  • The gross profit margin for WAFERGEN BIO-SYSTEMS INC is rather high; currently it is at 58.01%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -237.32% is in-line with the industry average.

You can view the full analysis from the report here:

Wafergen Bio-systems Ratings Report

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.